Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs Series C Financing Led by Surveyor Capital (a Citadel company) and Vida Ventures Differentiated mechanisms target RAS active conformation across all mutant forms, with potential to circumvent...